[Development and application of polysaccharide conjugate vaccine carrier protein].

Q3 Medicine

中华预防医学杂志 Pub Date : 2025-05-30 DOI:10.3760/cma.j.cn112150-20250326-00245

J X Li, X Ma, A Lin, H X Pan, B Hao, J Shao, Y Z Li, Y T Xu, Z J Shao, A Q Xu

{"title":"[Development and application of polysaccharide conjugate vaccine carrier protein].","authors":"J X Li, X Ma, A Lin, H X Pan, B Hao, J Shao, Y Z Li, Y T Xu, Z J Shao, A Q Xu","doi":"10.3760/cma.j.cn112150-20250326-00245","DOIUrl":null,"url":null,"abstract":"<p><p>The development of polysaccharide conjugate vaccines, which convert polysaccharide antigens into T-cell-dependent immunogens through covalent conjugation with protein carriers, represents a critical strategy for enhancing immune protection in infants and young children. Globally licensed conjugate vaccines currently employ carrier proteins including Tetanus Toxoid (TT), Diphtheria Toxoid (DT), and Cross-Reacting Material 197 (CRM197). Recent advances have focused on three key areas: novel carrier protein discovery, optimized conjugation strategies, and evaluation of immune interference during co-administration of multivalent formulations. These efforts aim to achieve broader serotype coverage, prolonged protective efficacy, and simplified immunization schedules. This review synthesizes recent progress in carrier protein development, encompassing vaccine design principles, manufacturing processes, safety profiles, and epidemiological effectiveness. Furthermore, it critically examines current selection criteria for carrier proteins, their clinical applications, and persistent challenges, providing strategic insights to inform future conjugate vaccine development and immunization policy optimization in China.</p>","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":"59 ","pages":"1-10"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华预防医学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112150-20250326-00245","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The development of polysaccharide conjugate vaccines, which convert polysaccharide antigens into T-cell-dependent immunogens through covalent conjugation with protein carriers, represents a critical strategy for enhancing immune protection in infants and young children. Globally licensed conjugate vaccines currently employ carrier proteins including Tetanus Toxoid (TT), Diphtheria Toxoid (DT), and Cross-Reacting Material 197 (CRM197). Recent advances have focused on three key areas: novel carrier protein discovery, optimized conjugation strategies, and evaluation of immune interference during co-administration of multivalent formulations. These efforts aim to achieve broader serotype coverage, prolonged protective efficacy, and simplified immunization schedules. This review synthesizes recent progress in carrier protein development, encompassing vaccine design principles, manufacturing processes, safety profiles, and epidemiological effectiveness. Furthermore, it critically examines current selection criteria for carrier proteins, their clinical applications, and persistent challenges, providing strategic insights to inform future conjugate vaccine development and immunization policy optimization in China.

查看原文本刊更多论文

多糖结合疫苗载体蛋白的研制与应用

多糖结合疫苗通过与蛋白质载体的共价结合将多糖抗原转化为t细胞依赖性免疫原，这是增强婴幼儿免疫保护的关键策略。全球许可的结合疫苗目前使用的载体蛋白包括破伤风类毒素（TT）、白喉类毒素（DT）和交叉反应物质197 （CRM197）。最近的进展集中在三个关键领域：新的载体蛋白的发现，优化的偶联策略，以及评估多价制剂共同给药期间的免疫干扰。这些努力的目的是实现更广泛的血清型覆盖，延长保护效力，并简化免疫接种时间表。本文综述了载体蛋白开发的最新进展，包括疫苗设计原则、制造工艺、安全性概况和流行病学有效性。此外，它还严格审查了目前载体蛋白的选择标准、临床应用和持续挑战，为中国未来的结合疫苗开发和免疫政策优化提供战略见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华预防医学杂志 Medicine-Medicine (all)

CiteScore

1.20

自引率

0.00%

发文量

12678

期刊介绍： Chinese Journal of Preventive Medicine (CJPM), the successor to Chinese Health Journal , was initiated on October 1, 1953. In 1960, it was amalgamated with the Chinese Medical Journal and the Journal of Medical History and Health Care , and thereafter, was renamed as People’s Care . On November 25, 1978, the publication was denominated as Chinese Journal of Preventive Medicine . The contents of CJPM deal with a wide range of disciplines and technologies including epidemiology, environmental health, nutrition and food hygiene, occupational health, hygiene for children and adolescents, radiological health, toxicology, biostatistics, social medicine, pathogenic and epidemiological research in malignant tumor, surveillance and immunization.